- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06322563
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC
March 20, 2024 updated by: Tianjin Medical University Cancer Institute and Hospital
An Open, Single-arm, Phase II Clinical Study Evaluating the Safety and Initial Efficacy of LTC004 in Combination With Regorafenib in the Treatment of Metastatic Colorectal Cancer
This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in combination with regorafenib in patients with mCRC.
A safety introductory trial was conducted to receive LTC004 in combination with regorafenib before starting the formal trial.
After completing a 28-day safety assessment, safety will be confirmed before entering the formal trial phase.
Further evaluation of the safety and efficacy of LTC004 in combination with regorafenib in the treatment of mCRC
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ting Deng
- Phone Number: 15802243063
- Email: 18526812877@163.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Aged 18 to 75 years.
- Non-radical resectable metastatic colorectal cancer confirmed by histology or cytology.
- Those who have progressed on, or are intolerant to, at least one prior first- and second-line systemic antitumor therapy for metastatic colorectal cancer. Patients must have received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy, and patients with mCRC who have previously received or are not candidates for anti-VEGF therapy, anti-epidermal growth factor receptor therapy (RAS wild-type).
- Pre-existing MMR, MSS, HER2, PD-L1, RAS, and BRAF status with corresponding supporting documentation.
- At least one measurable tumor lesion based on RECIST V1.1 criteria.
- ECOG PS ≤1.
- Expected survival ≥12 weeks.
- able to Swallow whole pills.
- Adequate organ function.
- Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for 6 months after the last infusion of LTC004.
- Understands and provides written informed consent and willing to follow the requirements specified in protocol.
Exclusion Criteria:
- History of severe hypersensitivity reactions to other mAbs.
- Untreated, unstable or uncontrolled central nervous system (CNS) metastases.
- Tumor invasion of vital arteries resulting in high risk of bleeding, significant risk of perforation or already formed fistulae.
- Patients with uncontrolled pleural effusion, pericardial effusion or abdominal effusion as judged by the investigator at screening.
- Patients with untreated or clinically symptomatic spinal cord compression that has not been controlled.
- Previous antitumor regimens include immunotherapies such as PD-1/L1 inhibitors, LAG3, TIGIT, IL-2, IL-15, CD3-like immunoagonists, and other cellular therapies, as well as other TKI agents (e.g., furaquintinib, regorafenib, etc.).
- ≥2 malignant tumors within 5 years prior to first dose of drug.
- Patients who have received any chemotherapy or anti-tumor monoclonal antibody drugs within 4 weeks prior to the first dose of study drug (excluding mitomycin and nitrosoureas within 6 weeks prior to the first dose of study drug; small molecule targeted drugs within 2 weeks prior to the first dose of study drug; Chinese medicine therapy (Chinese medicine therapy with clear anti-tumor indications in the package insert within 4 weeks prior to the first dose of study drug.
- Moderate to severe dyspnea at rest due to advanced cancer or its complications, severe primary lung disease, current need for continuous oxygen therapy, or clinically active interstitial lung disease (ILD) or pneumonia; Grade ≥3 interstitial pneumonia during prior antineoplastic therapy.
- Presence of severe infections including, but not limited to, bacteremia and severe pneumonia requiring hospitalization within 4 weeks prior to the first dose; active infections with CTCAE ≥ grade 2 requiring treatment with systemic antibiotics within 2 weeks prior to the first dose.
- History of serious cardiovascular disease.
- Previous total gastrectomy, chronic diarrhea, active inflammatory gastrointestinal disease, or any other condition causing malabsorption syndrome.
- Active bleeding disorder, including gastrointestinal bleeding, as evidenced by vomiting of blood, profuse hemoptysis, or black stools, in the 6 months prior to enrollment.
- Active hepatitis B (hepatitis B virus DNA measurement ≥1000 copies/mL or 200 IU/mL); hepatitis C infection (hepatitis C antibody positive and HCVRNA above the lower limit of detection in research centers); syphilis infection, active tuberculosis.
- Active, or previous autoimmune disease with potential for recurrence at the time of screening.
- Immunodeficiency diseases or history of such diseases, including a positive serologic test for human immunodeficiency virus (HIV).
- Arterial/venous thrombotic events within 6 months prior to first dose.
- Those who received radical radiation therapy within 4 weeks prior to the first dose and those who received palliative radiation within 14 days prior to the first dose.
- Use of live or attenuated vaccines within 4 weeks prior to the first dose, or anticipated need for live or attenuated vaccines during the study period.
- Major surgery (other than surgery for diagnostic purposes) within 4 weeks prior to the first dose, anticipation of major surgery (other than surgery for diagnostic purposes) during the study period, or diagnostic or low-invasive surgery within 7 days prior to the first dose (excluded for puncture biopsy).
- Adverse effects of prior antineoplastic therapy have not returned to a CTCAE version 5.0 grade rating of ≤ grade 1 (with the exception of alopecia and grade 2 neurotoxicity due to chemotherapeutic agents, and grade 2 hypothyroidism due to antineoplastic therapy).
- Patients with prior allogeneic bone marrow/hematopoietic stem cell transplantation or solid organ transplantation.
- Pregnant, lactating women.
- Subjects who, in the judgment of the investigator, have a history of other serious systemic disease or are unfit to participate in this trial for any other reason (the presence of psychiatric disorders in the patient that may affect compliance with the trial, alcohol, drug or substance abuse, etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Safety introduction trial:LTC004+regorafenib
LTC004 in combination with regorafenib safety introduction trial and completing a 28-day safety assessment
|
LTC004,90μg/kg,IV,Day 1,Q3W; Regorafenib:Orally once daily for the first 21 days of each cycle, with 28 days as 1 cycle.
Cycle 1 was dose-escalation with a starting dose of 80 mg/d, increasing by 40 mg per week until 160 mg/d, i.e., 80 mg/d in week 1 (D1~D7), 120 mg/d in week 2 (D8~D14), and 160 mg/d in week 3 (D15~D21);
|
Experimental: Formal trial phase:LTC004+regorafenib
After Safety introduction trial, safety will be confirmed before entering the formal trial phase.Further evaluation of the safety and efficacy of LTC004 in combination with regorafenib in the treatment of mCRC
|
LTC004,90μg/kg,IV,Day 1,Q3W; Regorafenib:Orally once daily for the first 21 days of each cycle, with 28 days as 1 cycle.
Cycle 1 was dose-escalation with a starting dose of 80 mg/d, increasing by 40 mg per week until 160 mg/d, i.e., 80 mg/d in week 1 (D1~D7), 120 mg/d in week 2 (D8~D14), and 160 mg/d in week 3 (D15~D21);
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-Emergent Adverse Events-Safety and Tolerability
Time Frame: up to 12 months
|
TEAE and changes in safety indicators (12-ECG,Laboratory inspection items,Cardiopulmonary function and so on)before and after administration
|
up to 12 months
|
SAE-Safety and Tolerability
Time Frame: up to 12 months
|
SAE and changes in safety indicators (12-ECG,Laboratory inspection items,Cardiopulmonary function and so on)before and after administration
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: up to 12 months
|
Antitumor efficacy of LTC004+Regorafenib
|
up to 12 months
|
DCR
Time Frame: up to 12 months
|
Antitumor efficacy of LTC004+Regorafenib
|
up to 12 months
|
PFS
Time Frame: up to 12 months
|
Antitumor efficacy of LTC004+Regorafenib
|
up to 12 months
|
OS
Time Frame: up to 12 months
|
Antitumor efficacy of LTC004+Regorafenib
|
up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
March 1, 2025
Study Completion (Estimated)
March 1, 2025
Study Registration Dates
First Submitted
February 26, 2024
First Submitted That Met QC Criteria
March 20, 2024
First Posted (Actual)
March 21, 2024
Study Record Updates
Last Update Posted (Actual)
March 21, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LTC004-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced/Metastatic Colorectal Cancer
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Holy Stone Healthcare Co., LtdCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Colorectal Cancer (mCRC)United States
-
Haihe Biopharma Co., Ltd.UnknownAdvanced Solid Tumor | Advanced/Metastatic Colorectal CancerChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors | Locally Advanced or Metastatic Breast or Colorectal CancerUnited States
-
University of ChicagoVerastem, Inc.RecruitingColorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingAdvanced/Metastatic Colorectal CancerChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingAdvanced Metastatic Colorectal CancerChina
-
Mirati Therapeutics Inc.Active, not recruitingMetastatic Colorectal Cancer | Advanced Colorectal CancerUnited States, Denmark, Finland, Italy, Spain, Belgium, Romania, Taiwan, Thailand, France, Germany, Korea, Republic of, China, Malaysia, Hong Kong, Australia, Austria, Puerto Rico, Singapore, Canada, Portugal, Poland, Greece, United Kingdom and more
-
US Oncology ResearchQuintiles, Inc.CompletedColorectal Neoplasms | Advanced Metastatic Colorectal CancerUnited States
Clinical Trials on LTC004+regorafenib
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruitingPancreas Cancer
-
LetolabNot yet recruitingLocally Advanced or Metastatic CRC
-
LetolabNot yet recruitingUnresectable or Metastatic Sarcoma
-
LetolabNot yet recruitingAdult Solid Tumor
-
Second Affiliated Hospital of Guangzhou Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... and other collaboratorsActive, not recruitingHepatocellular Carcinoma Non-resectableChina
-
Zhongda HospitalSun Yat-sen University; Jiangsu Cancer Institute & Hospital; Zhejiang University and other collaboratorsNot yet recruitingHepatocellular Carcinoma
-
Spanish Cooperative Group for the Treatment of...BayerCompletedColorectal Neoplasms | Metastatic DiseaseSpain
-
Rennes University HospitalRecruiting
-
Taipei Veterans General Hospital, TaiwanChang Gung Memorial Hospital; Koo Foundation Sun Yat-Sen Cancer CenterCompletedMetastatic Colorectal CancerTaiwan
-
Spanish Cooperative Group for the Treatment of...BayerCompletedStudy Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC (RE-ARRANGE)Metastatic Colorectal CancerSpain